quando operare??? l. toniolo chir. tor. cfvto. n0n1
TRANSCRIPT
Quando operare???
L. TonioloChir. Tor. CFVto
N0 N1
N2
Non chirurgico
N3
Non chirurgico !!!
Stadio IIIA (N2) Subsets
IIIA 1
IIIA 4
IIIA 2
IIIA 3
Metastasi “single station” identificate all’esame istologico definitivo (metastasi linfonodali microscopiche occulte)
Metastasi “single station” riconosciute intraoperatoriamente
N2 potenzialmente resecabile(identificato preoperatoriamente)
N2 “bulky multistation” non resecabile
Eterogeneità dell’ N2
Single N2 disease significantly better survival than multiple N2 disease
Tumor in the upper lobe significantly longer survival than with middle/lower lobe involvement
Single N2 disease with NSCLC in the upper lobe good candidates for pulmonary resection (3- and 5-y survival 74,9% and 53,5%)
Inoue M - J Thorac Cardiovasc Surg. 2004 Apr.; 127(4): 1100-6
N2 sottocarenale
Surgery for pts with T1-3 N2 NSCLC might be accettable if subcarinal lymph node metastasis is predicted to be absent
Iwasaki A - J Thorac Cardiovasc Surg. 2006 Feb; 54(1): 42-6
Skip phenomenon
M1 adenoca Adenoca T2 N0
Stadio IIIA (N2) Subsets
IIIA 1
IIIA 4
IIIA 2
IIIA 3
single-station metastases identified on the final pathological examination (occult microscopic nodal metastases)
single-station metastases recognized intraoperatively
potentially resectable N2 (identified preoperatively)
unresectable bulky multistation N2 disease
pN – Linfonodi regionali
pN0
pN3
pN1
pN2
Linfonodi liberi da malattia
Metastasi ai linfonodi ilari, peribronchiali o intrapolmonari ipsilaterali
Metastasi ai linfonodi mediastinici omolaterali
Metastasi ai linfonodi controlaterali (ilario mediastinici) o ai sovraclaveari